Disparities in Clinical Presentation, Management, and Outcomes With Invasive Cervical Cancer According to Insurance Status in the United States

2015 ◽  
Vol 93 (3) ◽  
pp. E352-E353
Author(s):  
T.M. Churilla ◽  
B. Egleston ◽  
Y. Dong ◽  
C.T. Murphy ◽  
P.R. Anderson
2005 ◽  
Vol 23 (30) ◽  
pp. 7454-7459 ◽  
Author(s):  
Marco A. Amendola ◽  
Hedvig Hricak ◽  
Donald G. Mitchell ◽  
Bradley Snyder ◽  
Dennis S. Chi ◽  
...  

Purpose To review the current utilization of diagnostic tests prescribed by the International Federation of Gynecology and Obstetrics (FIGO) clinical staging guidelines in the pretreatment work-up of invasive cervical cancer, and to compare the data with those of previous patterns of care studies. Patients and Methods This interdisciplinary American College of Radiology Imaging Network/Gynecologic Oncology Group prospective clinical trial was conducted between March 1, 2000, and November 11, 2002. Twenty-five participating institutions, all from the United States, enrolled a total of 208 patients. Only patients scheduled for surgery with biopsy-confirmed cervical cancer of clinical FIGO stage IB or higher were eligible. The patterns of care data analysis was based on 197 patients who met all inclusion criteria. The conventional FIGO-recommended tests used for pre-enrollment FIGO clinical stage classification were at the discretion of the treating physician; overall frequency of use was tabulated for each test. Results Use of cystoscopy (8.1%) and sigmoidoscopy or proctoscopy (8.6%) was significantly lower than in 1988 to 1989 (P < .0001 in each instance). Intravenous urography was used in only 1% of patients as compared with 42% in 1988 to 1989 and 91% in 1983. No patient included in the data analysis had barium enema or lymphangiography. Only 26.9% of patients had examination under anesthesia for FIGO clinical staging. Conclusion There is a large discrepancy between the diagnostic tests recommended by FIGO and the actual tests used for cervical cancer staging, suggesting a need to reassess the relevance of the FIGO guidelines to current clinical practice in the United States.


1990 ◽  
Vol 132 (3) ◽  
pp. 432-445 ◽  
Author(s):  
REGINA G. ZIEGLER ◽  
LOUISE A. BRINTON ◽  
RICHARD F. HAMMAN ◽  
HERMAN F. LEHMAN ◽  
ROBERT S. LEVINE ◽  
...  

2016 ◽  
Vol 141 (3) ◽  
pp. 516-523 ◽  
Author(s):  
Thomas Churilla ◽  
Brian Egleston ◽  
Yanqun Dong ◽  
Talha Shaikh ◽  
Colin Murphy ◽  
...  

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 5537-5537 ◽  
Author(s):  
E. L. Trimble ◽  
D. Gius ◽  
L. C. Harlan

5537 Background: On the basis of 5 NCI-sponsored randomized phase III trials, in 1999 the NCI issued a Clinical Announcement recommending that women with cervical cancer who require radiation also receive concomitant platinum-based chemotherapy. We undertook a population-based cohort study to determine whether the 1999 NCI Clinical Announcement was associated with changes in clinical practice in the United States. Methods: Through the NCI’s SEER program, we identified 973 women with invasive cervical cancer diagnosed in 1997, 773 diagnosed in 2000, and 1370 diagnosed in 2001. Hospital records were re-abstracted and treated physicians were contacted to verify initial therapy provided to each patient. Results: In multivariate analysis, we found a significant increase in the use of chemoradiation between 1997 and 2001/2001 among women with cervical cancer of all stages for which radiation would be appropriate. (see table ). Compared to women with well-differentiated tumors, women with moderately or poorly differentiated tumors were more likely to receive chemoradiation. Women aged 75 years or older were significantly less likely to receive chemoradiation than younger women. We saw no impact of race/ ethnicity or insurance status upon receipt of chemoradiation. Conclusions: Publication of the results from these 5 sutdies, extensive professional educational efforts, and the NCI’s Clinical Announcement were associated with widespread adoption of chemotherapy in the treatment of cervical cancer in the United States. [Table: see text] No significant financial relationships to disclose.


2009 ◽  
Vol 20 (7) ◽  
pp. 1129-1138 ◽  
Author(s):  
Jill Barnholtz-Sloan ◽  
Nitin Patel ◽  
Dana Rollison ◽  
Karl Kortepeter ◽  
Jill MacKinnon ◽  
...  

2012 ◽  
Vol 21 (9) ◽  
pp. 1402-1408 ◽  
Author(s):  
Christine M. Pierce Campbell ◽  
Lynette J. Menezes ◽  
Electra D. Paskett ◽  
Anna R. Giuliano

Sign in / Sign up

Export Citation Format

Share Document